- Home
- FLYE vs GLMD Comparison
FLYE vs GLMD Comparison
Compare FLYE & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | GLMD |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 4.0M |
| IPO Year | 2024 | 2013 |
Fundamental Metrics
Financial Performance| Metric | FLYE | GLMD |
|---|---|---|
| Price | $2.14 | $0.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 79.7K | ★ 305.4K |
| Earning Date | 04-21-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,427,163.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.41 |
| 52 Week High | $21.80 | $2.34 |
Technical Indicators
Market Signals| Indicator | FLYE | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 52.50 | 44.46 |
| Support Level | $1.77 | $0.53 |
| Resistance Level | $2.44 | $0.69 |
| Average True Range (ATR) | 0.34 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 30.68 | 56.17 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.